Recent Updates
Recently added Catalysts

Apellis Pharmaceuticals, Inc.

APLSFDA catalysts, PDUFA dates & pipeline intelligence
$41.03
▼ -0.02 · -0.05%

Last traded May 13, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full APLS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $16.1052W HIGH $41.14
Volume
68.61 M
Value Traded
2.82 B
Short % Float
9.94%
Days to Cover
3.1
-0.05%Week
+0.74%1 Month
+84.57%3 Month
+108.8%6 Month
-9.61%5 Year
+182.97%All Time

Cash Data

Unlock APLS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
5.25 B
EPS (TTM)
1.05
P/E Ratio
41.01
Ent. Value
5.32 B
Total Shares
127.85 M
Float Shares
108.16 M
Insiders
30.77%
Institutions
86.29%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every APLS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

APLS Catalyst Timeline

Dated clinical, regulatory and corporate events for Apellis Pharmaceuticals, Inc.

Unlock the full APLS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How APLS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-07-28EMPAVELI® (pegcetacoplan) PDUFA Date ApprovedPDUFA
Unlock 4 more APLS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Mar 2026; product lines: last four quarters to Mar 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
Syfovre
Empaveli Pegcetacoplan
Showing 14 of 15 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Pegcetacoplan Small moleculeNCT05809531C3GPhase 3 ACTIVE NOT_RECRUITING 237Jul 1, 2027
APL-2 Small moleculeNCT07213960FSGSPhase 2 RECRUITING 270Dec 1, 2029
APL-3007 Small moleculeNCT07215390Geographic Atrophy Secondary to Age-related Macular DegenerationPhase 2 RECRUITING 240Nov 1, 2027
Pegcetacoplan Small moleculeMarketedNCT03593200PNHPhase 3 COMPLETED 141Oct 22, 2019
Pegcetacoplan Small moleculeMarketedNCT02588833Paroxysmal Nocturnal HemoglobinuriaPhase 3 COMPLETED 124Aug 26, 2019
Pegcetacoplan Small moleculeMarketedNCT04770545Geographic Atrophy Secondary to Age-related Macular DegenerationPhase 3 COMPLETED 792Sep 5, 2025
APL-2 Small moleculeCompletedNCT03226678Warm Autoimmune Hemolytic AnemiaPhase 2 COMPLETED 24Sep 12, 2022
APL-2 Small moleculeCompletedNCT03453619IgA NephropathyPhase 2 COMPLETED 21Aug 26, 2023
Pegcetacoplan Small moleculeMarketedNCT03777332Geographic AtrophyPhase 2 COMPLETED 265Apr 1, 2021
Pegcetacoplan Small moleculeMarketedNCT05148299Transplant-Associated Thrombotic MicroangiopathyPhase 2 COMPLETED 12Dec 8, 2024
Pegcetacoplan Small moleculeMarketedNCT02461771Neovascular Age-Related Macular DegenerationPhase 1 COMPLETED 13Mar 8, 2016
APL-2 Small moleculeMarketedNCT04085601Paroxysmal Nocturnal HemoglobinuriaPhase 3 COMPLETED 53Jun 23, 2021
APL-2 Small moleculeMarketedNCT03525613Geographic AtrophyPhase 3 COMPLETED 1,258Jun 28, 2022
APL-2 Small moleculeMarketedNCT07214740Geographic Atrophy Secondary to Age-related Macular DegenerationPhase 3 COMPLETED 44Dec 12, 2025
Unlock the APLS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every APLS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
SYFOVRE® (pegcetacoplan injection)
PriorityFast Track
geographic atrophy (GA) secondary to age-related macular degeneration (AMD)Phase 32026-02-19more than 80 percent of participants who completed the OAKS and DERBY studies entered the GALE studyRead MoreApellis Announces Eight Oral Presentations at the 49th Macula Society Annual MeetingRead More
Scroll for more · summaries link to the source press release
Unlock every APLS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock APLS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Dunlop A. SinclairDirectorDisposition due to tender of shares -161,567 $0.00 05/14/2026
Unlock the full APLS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in APLS

Fund % of Portfolio Current MV Shares Owned Activity
Avoro Capital Advisors LLC 4.8 % (60 %) 491.70 M 12.22 M
Unlock every fund holding APLS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in APLS
Shares held by hedge funds each quarter, and who bought or sold.

APLS Institutional Ownership Trends

APLS Short Interest

Shares sold short, counted twice a month.

9.94%
Short % of Float
of tradable shares sold short
10.8M
Shares Sold Short
-24.5% vs prior count
3.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
3.5M
Avg Daily Volume
the average used for days to cover
Unlock APLS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock APLS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live APLS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock APLS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How APLS ranks across every disease it competes in

Competitive Position is a premium feature
See how APLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

APLS News

About Apellis Pharmaceuticals, Inc.

Waltham, MA 733 employees apellis.com
Headquarters100 FIFTH AVENUE, WALTHAM, MA, 02451
Founded2009
BIOPHARMAWATCH ELITE PLUS
Trade the next APLS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime